| Literature DB >> 34857031 |
Shiao Li Oei1, Thomas Rieser2, Sarah Becker3, Jessica Groß3, Harald Matthes1,2,4, Friedemann Schad1,5, Anja Thronicke6,7,8.
Abstract
BACKGROUND: The majority of breast cancer patients suffer from persistent impairments after completion of their primary oncological therapy. Cancer-related fatigue (CRF) in particular is a multidimensional syndrome having a profound negative impact on the quality of life. To counter CRF symptoms, physical activities are suggested as first-line interventions, mind-body therapies have been shown to be effective, and music therapy can also reduce anxiety and stress in breast cancer patients. Tango therapy that combines various elements can have an impact on physical, psychological, and cognitive abilities and could therefore have a beneficial effect on breast cancer patients. The purpose of this study is to investigate whether a 6-week tango module is suited as a therapeutic approach for people after primary breast cancer therapy to favorably influence their quality of life, especially CRF levels.Entities:
Keywords: Breast cancer; Dance; Fatigue; Health-related quality of life; Insomnia
Mesh:
Year: 2021 PMID: 34857031 PMCID: PMC8637025 DOI: 10.1186/s13063-021-05869-3
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Fig. 1Flow diagram of the study participants according to the Consolidated Standards of Reporting Trials (CONSORT 2010), illustrating the participant’s timeline
Six-week Argentine tango protocol for people with breast cancer and fatigue
| Session | Description of the activities |
|---|---|
| 1 | |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 |
| Title {1} | TANGO - Effect of Tango Argentino on cancer-associated fatigue in breast cancer patients: Study Protocol for a Randomized Controlled Trial |
|---|---|
| Trial registration {2a and 2b}. | Trial registration number DRKS00021601. Retrospectively registered on 21 August 2020. |
| Protocol version {3} | The current protocol version is version 2.0, dated from 23 March 2020. |
| Funding {4} | The primary sponsor is the Forschungsinstitut Havelhöhe (FIH) gGmbH am Gemeinschaftskrankenhaus Havelhöhe. |
| Author details {5a} | SLO, MH, FS, AT: Research Institute Havelhöhe gGmbH at Hospital Gemeinschaftskrankenhaus Havelhöhe, Berlin, Germany; TR, HM, AT: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Social Medicine, Epidemiology and Health Economics, Berlin, Germany; SB, JG: Hospital Gemeinschaftskrankenhaus Havelhöhe Breast Cancer Centre, Berlin, Germany; MH: Medical Clinic for Gastroenterology, Infectiology and Rheumatology CBF, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, MH, FS: Hospital Gemeinschaftskrankenhaus Havelhöhe, Interdisciplinary Oncology and Palliative Care, Berlin |
| Name and contact information for the trial sponsor {5b} | Research Institute Havelhöhe gGmbH at Hospital Gemeinschaftskrankenhaus Havelhöhe, Berlin, Germany Trial’s principal investigator: Friedemann Schad, fschad@havelhoehe.de; scientific coordinator: Anja Thronicke, anja.thronicke@havelhoehe.de |
| Role of sponsor {5c} | The sponsor is non-commercial. The sponsor ensures quality management, qualified and trained personnel, study protocol compliance, submission of relevant study documents to the ethics committee and regulatory authorities. He supports the study with trial unit facilities and study nurses. |